|
|
Vol. 17.11 – 26 June, 2026
|
|
|
|
|
|
|
|
|
In a preclinical human orthotopic metastatic CRPC mouse model, treatment with therapeutic monoclonal antibodies effectively prevents the nuclear accumulation of TβRI-ICD, inhibits epithelial-to-mesenchymal transition, and suppresses tumor growth, invasion, and metastasis. [Signal Transduction and Targeted Therapy]
|
|
|
|
|
|
PUBLICATIONSListed by the impact factor of the journal
|
|
|
|
|
|
Investigators developed a programmable RNA engineering platform, termed the 3′UTR CRISPR/dCas13 Engineering System, to precisely manipulate mRNA alternative polyadenylation in vivo. [Nature Biomedical Engineering]
|
|
|
|
|
|
To define mechanisms underpinning metastatic heterogeneity in late-stage disease, scientists employed single-cell multi-omics and whole-genome sequencing to deeply profile 34 metastatic lesions obtained from patients through rapid autopsy.
[Nature Communications]
|
|
|
|
|
|
Researchers provided distinct insight into how FOXA1 forkhead DNA-binding domain (FKHD) mutations drive prostate cancer progression and highlighted potential therapeutic targets in tumors. [Communications Biology]
|
|
|
|
|
|
Investigators uncovered a previously unrecognized triad of ERG-driven processes –dedifferentiation, senescence, and inflammation– that may underpin its oncogenic potential and shape prostate cancer initiation and therapeutic response.
[Molecular Cancer Research]
|
|
|
|
|
|
Scientists revealed that miR-6833-3p drives prostate carcinogenesis and enhances tumor-initiating cell properties through suppression of the NUMB-mediated NOTCH signaling axis. [Cell Cycle]
|
|
|
|
|
|
|
|
The authors summarize the key molecular drivers of prostate cancer resistance and evaluate emerging invasive biomarkers with potential clinical utility.
[Molecular Aspects of Medicine]
|
|
|
|
|
|
Scientists discuss the role of glycans in fundamental mechanisms controlling prostate cancer growth, metastasis, and immune evasion. [Oncogene]
|
|
|
|
|
|
|
|
Researchers from the UCLA Health Jonsson Comprehensive Cancer Center have received a $1.7 million grant to develop new strategies to improve CAR T-cell therapies for metastatic CRPC. [UCLA Health]
|
|
|
|
|
|
|
|
July 28 – 30, 2026 Boston, Massachusetts, United States
|
|
|
|
|
|
|
|
|
|
|
University of Oxford- Oxford, England, United Kingdom
|
|
|
|
|
|
|
University of Oxford – Oxford, England, United States
|
|
|
|
|
|
|
City of Hope – Duarte, California, United States
|
|
|
|
|
|
|
The University of Texas MD Anderson Cancer Center – Houston, Texas, United States
|
|
|
|
|
|
|
The University of Hong Kong – Hong Kong
|
|
|
|
|
|